Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7020554 | 0.81 | — | — | |
| SCHEMBL29907806 | 0.81 | RNPEP (0.58) | ACE2RNPEPFOLH1CHRM1AKR1A1 | |
| SCHEMBL30542 | 0.81 | — | — | |
| SCHEMBL2976825 | 0.80 | — | — | |
| SCHEMBL204061 | 0.80 | — | — | |
| SCHEMBL2977541 | 0.80 | — | — | |
| SCHEMBL5476409 | 0.80 | RNPEP (0.68) | RNPEPBLMFOLH1CHRM1AKR1A1 | |
| SCHEMBL8939040 | 0.79 | BLM (0.73) | ACE2BLMCHRM1AKR1A1CHRM3 | |
| SCHEMBL414209 | 0.79 | RNPEP (0.58) | ACE2RNPEPFOLH1CHRM1AKR1A1 | |
| SCHEMBL31632559 | 0.79 | BLM (0.73) | ACE2BLMCHRM1AKR1A1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240779-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISORDERS | CELLIX BIO PRIVATE LTD (IN) | 2020-10-28 | — | — | EP | disclosed |
| US-9932294-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2018-04-03 | — | — | US | disclosed |
| EP-2542547-B1 | COMPOUNDS, COMPOSITIONS, FORMULATIONS AND THEIR USES IN THE TREATMENT OF DISEASES RELATED TO COPPER RETENTION OR HEPATIC DISORDERS | KRISANI BIOSCIENCE (P) LTD (IN) | 2018-01-24 | — | — | EP | disclosed |
| EP-3240779-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY AND NEUROLOGICAL DISORDERS | Cellixbio Private Limited (IN) | 2017-11-08 | — | — | EP | disclosed |
| EP-3226855-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2017-10-11 | — | — | EP | disclosed |
| US-9771355-B2 | Compositions and methods for the treatment of epilepsy and neurological disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2017-09-26 | — | — | US | disclosed |
| WO-2017060914-A2 | PENICILLAMINE AND ITS DERIVATIVES ARE USED IN THE TREATMENT OF COPPER TOXICITY AND NASH | Krisani Biosciences (P) Ltd. (IN) | 2017-04-13 | — | — | WO | disclosed |
| EP-2580204-B1 | CYSTEAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NASH | KRISANI BIOSCIENCE (P) LTD (IN) | 2017-03-08 | — | — | EP | disclosed |
| WO-2016088132-A9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-09-01 | — | — | WO | disclosed |
| WO-2016088132-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-06-09 | — | — | WO | disclosed |
| WO-2011107877-A2 | COMPOUNDS AND COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO COPPER RETENTION | KANDULA MAHESH (IN) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107867-A2 | COMPOUND AND COMPOSITION AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO COPPER RETENTION | KANDULA MAHESH (IN) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107881-A2 | COMPOUNDS, COMPOSITIONS, FORMULATIONS AND THEIR USES THEREOF | KANDULA MAHESH (IN) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011107870-A2 | COMPOUNDS AND COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO COPPER RETENTION | KANDULA MAHESH (IN) | 2011-09-09 | — | — | WO | disclosed |
| US-20110218238-A1 | COMPOUNDS, COMPOSITIONS, FORMULATIONS AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218237-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD. (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218235-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | KRISHANI BIOSCIENCES (P) LTD (IN) | 2011-09-08 | — | — | US | disclosed |
| EP-0947503-B1 | 6,8-Dimethylmercaptooctanoic acid derivatives substituted on 6-S and/or 8-S by the 3-methylthiopropanoyl radical and pharmaceutical compositions for the treatment of cancerous tumours | GALDERMA RES & DEV (FR) | 2001-11-21 | — | — | EP | disclosed |
| EP-0947503-A1 | 6,8-Dimethylmercaptooctanoic acid derivatives substituted on 6-S and/or 8-S by the 3-methylthiopropanoyl radical and pharmaceutical compositions for the treatment of cancerous tumours | Galderma Research & Development, S.N.C. (FR) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218237-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | SLC26A4, SLC26A3, SLC10A1 | ACE2 3401/4885RNPEP 4679/4885BLM 2630/4885 |
| US-20110218236-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | SLC26A4, SLC26A3, SLC10A1 | ACE2 3401/4885RNPEP 4679/4885BLM 2630/4885 |
| US-20110218238-A1 | COMPOUNDS, COMPOSITIONS, FORMULATIONS AND THEIR USES THEREOF | SLC10A1, ABCB11, NPC1L1 | ACE2 3075/4885RNPEP 4442/4885BLM 1657/4885 |
| US-20110218235-A1 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF | SLC10A1, CYP7A1, SLC39A11 | ACE2 2721/4885RNPEP 4513/4885BLM 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.